Home » Stocks » Brickell Biotech

Brickell Biotech, Inc. (BBI)

Stock Price: $0.720 USD -0.109 (-13.19%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $0.730 +0.010 (1.38%) Oct 22, 7:32 PM

Stock Price Chart

Key Info

Market Cap 23.53M
Revenue (ttm) 3.51M
Net Income (ttm) -24.87M
Shares Out 32.68M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $0.720
Previous Close $0.830
Change ($) -0.109
Change (%) -13.19%
Day's Open 0.810
Day's Range 0.712 - 0.810
Day's Volume 3,021,728
52-Week Range 0.710 - 4.110

More Stats

Market Cap 23.53M
Enterprise Value 2.43M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 32.68M
Float 29.83M
EPS (basic) -5.05
EPS (diluted) -3.17
FCF / Share -3.23
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 256,851
Short Ratio 0.15
Short % of Float 0.86%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.71
PB Ratio 1.25
Revenue 3.51M
Operating Income -26.12M
Net Income -24.87M
Free Cash Flow -38.16M
Net Cash 21.10M
Net Cash / Share 0.65
Gross Margin -350.84%
Operating Margin -745.25%
Profit Margin -711.80%
FCF Margin -1,088.67%
ROA -104.72%
ROE n/a
ROIC -633.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.50*
(663.78% upside)
Low
5.00
Current: $0.720
High
6.00
Target: 5.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue7.9210.8913.8214.5320.9515.227.7217.5230.028.71
Revenue Growth-27.29%-21.21%-4.9%-30.64%37.67%97.16%-55.94%-41.64%244.6%-
Gross Profit7.9210.897.348.2410.024.39-4.984.4619.75-2.73
Operating Income-24.47-8.45-13.39-9.18-9.40-16.63-31.35-23.43-7.82-31.22
Net Income-23.88-9.24-12.96-8.97-9.24-16.49-31.24-22.90-7.28-30.39
Shares Outstanding3.020.591.841.431.311.271.241.231.030.86
Earnings Per Share-4.50-25.85-7.07-6.30-7.07-13.02-25.20-18.90-7.00-35.70
Operating Cash Flow-35.983.97-8.60-8.39-6.95-9.81-29.80-17.23-3.64-28.23
Capital Expenditures-0.01-0.01-0.08-0.26-0.07-0.07-0.28-0.64-0.26-0.35
Free Cash Flow-35.993.96-8.68-8.64-7.02-9.88-30.08-17.87-3.90-28.58
Cash & Equivalents11.738.0760.6938.9339.9547.1553.5083.8650.4355.27
Total Debt0.074.64--------
Net Cash / Debt11.663.4360.6938.9339.9547.1553.5083.8650.4355.27
Assets18.148.7580.4952.2849.9157.9866.3596.5268.7772.91
Liabilities10.5722.0816.927.154.526.064.947.448.438.55
Book Value7.57-71.6263.5845.1445.3951.9261.4189.0960.3564.36
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Brickell Biotech, Inc.
Country United States
Employees 15
CEO Robert B. Brown

Stock Information

Ticker Symbol BBI
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: BBI

Description

Brickell Biotech, a clinical-stage pharmaceutical company, focuses on the development of various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in Phase III clinical trial for patients with axillary hyperhidrosis. It is also developing therapeutics for cutaneous T-cell lymphoma, psoriasis, and other dermatological conditions. Brickell Biotech, Inc. has collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19 in the United States. The company was founded in 2009 and is based in Boulder, Colorado.